Loading...Loading...The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company’s popular weight-loss drug, Wegovy, in the basic insurance coverage.The institute’s recommendation, delivered on Tuesday, cited insufficient clarity on whether Wegovy’s health benefits justify its costs.Related: Bernie Sanders Targets High Prices of Ozempic and Wegovy In US.Al ...

In the latest market close, Novo Nordisk (NVO) reached $140.87, with a -0.37% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.64%. Elsewhere, the Dow saw an upswing of 1.85%, while the tech-heavy Nasdaq appreciated by 0.2%.The drugmaker's stock has climbed by 0.73% in the past month, exceeding the Medical sector's gain of 0.71% and lagging the S&P 500's gain of 3.82%.Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upc ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Novo Nordisk (NVO) was once again in the news on Jul 12 after the University of Oxford announced results from an exploratory one-year study of semaglutide, a GLP-1 receptor agonist, showing that the drug was not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications. On the contrary, treatment with semaglutide was associated with benefits like lowering the risk of cognitive problems and nicotine misuse. This opens the scope for further evaluation of the drug ...

Hopes are high about one of its next-gen candidates.Novo Nordisk (NVO 1.64%) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practically a given among many investors.And now, there's what could be 80 billion more reasons to believe in its stock rising and rising for years to come. So without further ado, let's explore why the bul ...

Key TakeawaysAmerican depositary receipts (ADRs) of Novo Nordisk rose in intraday trading Friday after an Oxford study showed the Danish company’s Ozempic diabetes drug was linked to lower rates of dementia.The drug also has been linked to a reduction in a range of mental problems, according to an article in The Lancet’s eClinicalMedicine journal.The study is the latest to show that semaglutide, the active ingredient in both Novo Nordisk’s Ozempic and its obesity medicine Wegovy, can treat more than diabete ...

Novo Nordisk (NVO) has rallied 38% in the year-to-date period compared with the industry’s 23.3% growth, as seen in the chart below. The stock has also outperformed the sector and the S&P 500. NVO is currently trading near the 52-week high. Novo Nordisk Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchNovo Nordisk, a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its GLP-1 agonist, semaglutide, which is approved as an Ozempic ...

Novo Nordisk (NVO) announced that it has received a complete response letter from the FDA for its biologics license application (“BLA”) for once-weekly basal insulin icodec.The BLA seeks approval for once-weekly basal insulin icodec for the treatment of diabetes mellitus. The application was submitted in April 2023.The FDA requested information related to the manufacturing process and the type 1 diabetes indication before it can complete the review of the application.Novo is evaluating the content of the CR ...

Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufacturing process and the type 1 diabetes indication before the review of the application can be completed. Novo Nordisk is evaluating the content of the CRL and will work closely wit ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...